Low density lipoprotein increased adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 7,533 adverse event reports that record the MedDRA preferred term Low density lipoprotein increased. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 514 reports in the 12 months to June 2026 and 588 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 976 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 514 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 26.6% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 148 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Low density lipoprotein increased name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	54
Accutane	Retinoid	27
Actemra	Interleukin-6 receptor antagonist	50
Afinitor	Kinase inhibitor	23
Alirocumab	PCSK9 inhibitor	27
Alirocumab Prefilled Pen		50
Amlodipine	Calcium channel blocker	31
Amnesteem	Retinoid	18
Ampyra	Potassium channel blocker	21
Androgel		10
Arimidex	Aromatase inhibitor	18
Aripiprazole	Atypical antipsychotic	14
Aspirin	Nonsteroidal anti-inflammatory drug	43
Atazanavir	Protease inhibitor	11
Atenolol	beta-Adrenergic blocker	33
Atorvastatin		119
Atorvastatin calcium	HMG-CoA reductase inhibitor	72
Aubagio	Pyrimidine synthesis inhibitor	12
Avonex	Interferon beta	20
Basiliximab	Interleukin-2 receptor blocking antibody	14
Bevacizumab	Vascular endothelial growth factor inhibitor	11
Bisoprolol	beta-Adrenergic blocker	36
Caduet	Calcium channel blocker	11
Carboplatin	Platinum-based drug	10
Celebrex	Nonsteroidal anti-inflammatory drug	22
Chantix	Partial cholinergic nicotinic agonist	28
Citalopram	Serotonin reuptake inhibitor	13
Clobetasol		13
Clozapine	Atypical antipsychotic	21
Clozaril	Atypical antipsychotic	33
Combivir	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	11
Cosentyx	Interleukin-17A antagonist	45
Crestor	HMG-CoA reductase inhibitor	412
Cyclosporine	Calcineurin inhibitor immunosuppressant	20
Cymbalta		24
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	13
Desvenlafaxine succinate	Serotonin and norepinephrine reuptake inhibitor	11
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	10
Digoxin	Cardiac glycoside	12
Diovan	Angiotensin 2 receptor blocker	18
Dupixent	Interleukin-4 receptor alpha antagonist	25
Efavirenz	Human immunodeficiency virus 1 Non-Nucleoside analog reverse transcriptase inhibitor	17
Enbrel	Tumor necrosis factor blocker	69
Entresto	Angiotensin 2 receptor blocker	29
Euthyrox		11
Evolocumab	PCSK9 inhibitor	10
Ezetimibe	Dietary cholesterol absorption inhibitor	208
Fenofibrate	Peroxisome proliferator receptor alpha agonist	14
Forteo	Parathyroid hormone analog	20
Fosamax	Bisphosphonate	17
Furosemide	Loop diuretic	30
Genotropin		40
Genotropin Mq		32
Gilenya	Sphingosine 1-phosphate receptor modulator	141
Humira		96
Inclisiran		33
Insulin	Insulin analog	10
Invokana	Sodium-Glucose cotransporter 2 inhibitor	11
Ivabradine hydrochloride		10
Jakafi	Janus kinase inhibitor	32
Juxtapid		158
Kaletra	Cytochrome P450 3A inhibitor	20
Kanuma		19
Lamivudine	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	28
Leflunomide	Antirheumatic agent	13
Leqvio		464
Lipitor	HMG-CoA reductase inhibitor	357
Lisinopril	Angiotensin converting enzyme inhibitor	23
Lorbrena	Kinase inhibitor	19
Lorlatinib	Kinase inhibitor	71
Lovaza		73
Lyrica		33
Metformin	Biguanide	38
Metformin hcl	Biguanide	10
Metgluco		24
Methotrexate	Folate analog metabolic inhibitor	50
Methotrexate sodium	Folate analog metabolic inhibitor	12
Methylprednisolone	Corticosteroid	14
Metoprolol	beta-Adrenergic blocker	10
Mounjaro	GLP-1 receptor agonist	11
Mycophenolate mofetil	Antimetabolite immunosuppressant	10
Myfortic	Antimetabolite immunosuppressant	18
Myorisan		22
Neurontin		10
Nexium	Proton pump inhibitor	15
Niaspan		118
Novothyrox		20
Nutropin Aq		11
Nuvaring	Estrogen	17
Ocrevus	CD20-directed cytolytic antibody	10
Olanzapine	Atypical antipsychotic	13
Omacor		10
Omeprazole	Proton pump inhibitor	17
Orgovyx	Gonadotropin releasing hormone receptor antagonist	13
Ozempic	GLP-1 receptor agonist	13
Pantoprazole	Proton pump inhibitor	22
Praluent	PCSK9 inhibitor	316
Pravachol		10
Pravastatin		15
Prednisone	Corticosteroid	55
Premarin	Estrogen	12
Prolia	RANK ligand inhibitor	75
Prozac	Serotonin reuptake inhibitor	10
Quetiapine	Atypical antipsychotic	13
Ramipril	Angiotensin converting enzyme inhibitor	19
Rebif	Interferon beta	14
Remicade	Tumor necrosis factor blocker	22
Repatha	PCSK9 inhibitor	1,116
Rinvoq	Janus kinase inhibitor	75
Ritonavir	Cytochrome P450 3A inhibitor	22
Rituximab	CD20-directed cytolytic antibody	20
Rosuvastatin	HMG-CoA reductase inhibitor	126
Rosuvastatin calcium	HMG-CoA reductase inhibitor	28
Seroquel	Atypical antipsychotic	26
Simcor		20
Simvastatin	HMG-CoA reductase inhibitor	83
Skyclarys		15
Skyrizi	Interleukin-23 antagonist	13
Somavert		24
Spironolactone	Aldosterone antagonist	12
Stelara	Interleukin-12 antagonist	14
Strensiq		16
Sulfasalazine	Aminosalicylate	12
Sustiva		10
Tacrolimus	Calcineurin inhibitor immunosuppressant	30
Tasigna	Kinase inhibitor	31
Tecfidera		18
Tegsedi		10
Telmisartan	Angiotensin 2 receptor blocker	15
Tepezza		25
Ticagrelor	P2Y12 platelet inhibitor	15
Tricor	Peroxisome proliferator receptor alpha agonist	22
Trilipix		34
Triumeq	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	10
Tymlos		10
Tysabri	Integrin receptor antagonist	13
Valsartan	Angiotensin 2 receptor blocker	21
Vascepa		16
Viagra	Phosphodiesterase 5 inhibitor	10
Vioxx		96
Welchol		10
Xarelto	Factor Xa inhibitor	13
Xeljanz	Janus kinase inhibitor	145
Zetia	Dietary cholesterol absorption inhibitor	76
Zidovudine	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	15
Zocor	HMG-CoA reductase inhibitor	24
Zoloft	Serotonin reuptake inhibitor	14
Zyprexa	Atypical antipsychotic	72

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 40 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Low density lipoprotein increased name, in order of name
Class	Reports with this term
Angiotensin 2 receptor blocker	101
Angiotensin converting enzyme inhibitor	44
Antimetabolite immunosuppressant	30
Aromatase inhibitor	40
Atypical antipsychotic	285
beta-Adrenergic blocker	103
Biguanide	51
Calcineurin inhibitor immunosuppressant	62
Calcium channel blocker	51
CD20-directed cytolytic antibody	40
Corticosteroid	113
Cytochrome P450 3A inhibitor	47
Dietary cholesterol absorption inhibitor	293
Estrogen	42
Folate analog metabolic inhibitor	62
GLP-1 receptor agonist	47
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	76
HMG-CoA reductase inhibitor	1,120
Human immunodeficiency virus 1 Non-Nucleoside analog reverse transcriptase inhibitor	40
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	46
Interferon beta	34
Interleukin-17A antagonist	49
Interleukin-4 receptor alpha antagonist	25
Interleukin-6 receptor antagonist	60
Janus kinase inhibitor	277
Kinase inhibitor	192
Loop diuretic	34
Nonsteroidal anti-inflammatory drug	89
P2Y12 platelet inhibitor	35
Partial cholinergic nicotinic agonist	28
PCSK9 inhibitor	1,469
Peroxisome proliferator receptor alpha agonist	40
Proton pump inhibitor	54
RANK ligand inhibitor	77
Retinoid	65
Serotonin and norepinephrine reuptake inhibitor	29
Serotonin reuptake inhibitor	55
Sodium-Glucose cotransporter 2 inhibitor	39
Sphingosine 1-phosphate receptor modulator	141
Tumor necrosis factor blocker	91

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Low density lipoprotein increased, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Low density lipoprotein increased
Age	Reports	Share
Under 2	15	0.2%
2 to 11	45	0.6%
12 to 17	58	0.8%
18 to 44	777	10.3%
45 to 64	2,006	26.6%
65 to 74	1,016	13.5%
75 and over	523	6.9%
Age not given	3,093	41.1%

Sex of the patient in the reports that record Low density lipoprotein increased
Sex	Reports	Share
Female	3,810	50.6%
Male	2,836	37.6%
Unknown or not given	887	11.8%

Age and sex are as the report gives them. 69.4% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Low density lipoprotein increased: adverse event reports that record this term. https://reportedreactions.com/reaction/low-density-lipoprotein-increased/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Low density lipoprotein increased mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page